Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies

Genes Chromosomes and Cancer

Volumn 55, Issue 5, 2016, Pages 428-441

  Van Roosbroeck, Katrien ^a,b   Ferreiro, Julio Finalet ^a   Tousseyn, Thomas ^a   van der Krogt, Jo Anne ^a   Michaux, Lucienne ^a   Pienkowska Grela, Barbara ^c   Theate, Ivan ^d   De Paepe, Pascale ^e   Dierickx, Daan ^f   Doyen, Chantal ^g   Put, Natalie ^a   Cools, Jan ^a,b   Vandenberghe, Peter ^a   Wlodarska, Iwona ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e Department of Pathology ^*  (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; CD274 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE REARRANGEMENT; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; INTERPHASE; LARGE CELL LYMPHOMA; LYMPHOMA; MALE; MIDDLE AGED; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; T CELL LYMPHOMA; YOUNG ADULT; CHROMOSOME BANDING PATTERN; GENE EXPRESSION PROFILING; GENETICS; KARYOTYPING; MUTATION;

ANTIGENS, CD274; CHROMOSOME BANDING; GENE EXPRESSION PROFILING; HUMANS; JANUS KINASE 2; KARYOTYPING; LYMPHOMA; MUTATION;

EID: 84962892206     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22345     Document Type: Article

References (41)

1. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. 2011. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 17:4232-4244.
2. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. 2015. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319.
3. Armand P. 2015. Checkpoint blockade in lymphoma. Blood 125:393-400.
4. Bentz M, Barth TF, Bruderlein S, Bock D, Schwerer MJ, Baudis M, Joos S, Viardot A, Feller AC, Muller-Hermelink HK, Lichter P, Dohner H, Moller P. 2001. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 30:393-401.
5. Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, Raderer M, Preusser M. 2014. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol 33:42-49.
6. Berry WL, Janknecht R. 2013. KDM4/JMJD2 histone demethylases: Epigenetic regulators in cancer cells. Cancer Res 73:2936-2942.
7. Blank C, Mackensen A. 2007. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56:739-745.
8. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. 2013. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19:3462-3473.
9. Chin YW, Han SY. 2015. KDM4 histone demethylase inhibitors for anti-cancer agents: A patent review. Expert Opin Ther Pat 25:135-144.
10. De Keersmaecker K, Michaux L, Bosly A, Graux C, Ferreiro JF, Vandenberghe P, Cools J, Wlodarska I. 2012. Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL. Blood 119:3864-3866.
11. Finalet Ferreiro J, Morscio J, Dierickx D, Marcelis L, Vandenberghe P, Gheysens O, Verhoef G, Zamani M, Tousseyn T, Wlodarska I. EBV-positive and EBV-negative posttransplant diffuse large B-cell lymphomas have distinct genomic and transcriptomic features. Am J Transplant January 2016.
12. Ghoreschi K, Laurence A, O'Shea JJ. 2009. Janus kinases in immune cell signaling. Immunol Rev 228:273-287.
13. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA. 2010. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268-3277.
14. Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA. 2014. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res 20:2674-2683.
15. Joos S, Kupper M, Ohl S, von BF, Mechtersheimer G, Bentz M, Marynen P, Moller P, Pfreundschuh M, Trumper L, Lichter P. 2000. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60:549-552.
16. Kawamura M, Taki T, Kaku H, Ohki K, Hayashi Y. 2015. Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21). Genes Chromosomes Cancer 54:401-408.
17. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704.
18. Kuppers R, Dalla-Favera R. 2001. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20:5580-5594.
19. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F, Odero MD, Bauters M, Froyen G, Marynen P, Vandenberghe P, Wlodarska I, Meijerink JP, Cools J. 2007. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 39:593-595.
20. Li Y, Wang J, Li C, Ke XY. 2012. Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymphoma 53:2015-2023.
21. Martin-Subero JI, Ibbotson R, Klapper W, Michaux L, Callet-Bauchu E, Berger F, Calasanz MJ, De Wolf-Peeters C, Dyer MJ, Felman P, Gardiner A, Gascoyne RD, Gesk S, Harder L, Horsman DE, Kneba M, Kuppers R, Majid A, Parry-Jones N, Ritgen M, Salido M, Sole F, Thiel G, Wacker HH, Oscier D, Wlodarska I, Siebert R. 2007. A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. Leukemia 21:1532-1544.
22. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, Griffith M, Heravi MA, Senz J, Melnyk N, Pacheco M, Marra MA, Hirst M, Nielsen TO, Sahinalp SC, Huntsman D, Shah SP. 2011. deFuse: An algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 7:e1001138.
23. Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S, Tzankov A. 2009. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 22:476-487.
24. Melzner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF, Leithauser F, Moller P. 2005. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105:2535-2542.
25. Put N, Van Roosbroeck K, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L. 2012. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: A subgroup with an aggressive disease course. Ann Hematol 91:863-873.
26. Rouhigharabaei L, Ferreiro JF, Put N, Michaux L, Tousseyn T, Lefebvre C, Gardiner A, De Kelver W, Demuynck H, Verschuere J, Theate I, Vicente C, Vandenberghe P, Cools J, Wlodarska I. 2013. BMI1, the polycomb-group gene, is recurrently targeted by genomic rearrangements in progressive B-cell leukemia/lymphoma. Genes Chromosomes Cancer 52:928-944.
27. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Moller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM. 2010. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18:590-605.
28. Shaffer LG, McGowfan-Jordan J, Schmid M. 2013. An International System for Human Cytogenetic Nomenclature (2013). Basel, Switzerland: S. Karger AG.
29. Sharma P, Wagner K, Wolchok JD, Allison JP. 2011. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer 11:805-812.
30. Skoda RC, Duek A, Grisouard J. 2015. Pathogenesis of myeloproliferative neoplasms. Exp Hematol 43:599-608.
31. Springuel L, Renauld JC, Knoops L. 2015. JAK kinase targeting in hematologic malignancies: A sinuous pathway from identification of genetic alterations towards clinical indications. Haematologica 100:1240-1253.
32. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD. 2011. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471:377-381.
33. Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson AW, Kridel R, Telenius A, Scott DW, Savage KJ, Shah SP, Gascoyne RD, Steidl C. 2014. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123:2062-2065.
34. Twa DD, Mottok A, Chan FC, Ben-Neriah S, Woolcock BW, Tan KL, Mungall AJ, McDonald H, Zhao Y, Lim RS, Nelson BH, Milne K, Shah SP, Morin RD, Marra MA, Scott DW, Gascoyne RD, Steidl C. 2015. Recurrent genomic rearrangements in primary testicular lymphoma. J Pathol 236:136-141.
35. Twa DD, Steidl C. 2015. Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leuk Lymphoma 56:2239-2250.
36. Vainchenker W, Dusa A, Constantinescu SN. 2008. JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 19:385-393.
37. Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, Cauwelier B, De PP, Verhoef G, Marynen P, Vandenberghe P, De Wolf-Peeters C, Cools J, Wlodarska I. 2011. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 117:4056-4064.
38. Vandenberghe P, Wlodarska I, Tousseyn T, Dehaspe L, Dierickx D, Verheecke M, Uyttebroeck A, Bechter O, Delforge M, Vandecaveye V, Brison N, Verhoef G, Legius E, Amant F, Vermeesch J. 2015. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: A technical proof-of-principle study. Lancet Haematol 2:e55-e65.
39. Vinatzer U, Gollinger M, Mullauer L, Raderer M, Chott A, Streubel B. 2008. Mucosa-associated lymphoid tissue lymphoma: Novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res 14:6426-6431.
40. Willis TG, Dyer MJ. 2000. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96:808-822.
41. Zou W, Chen L. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8:467-477.